melitracen
Sign in to saveMelitracen (brand names Melixeran, Trausabun) is a tricyclic antidepressant (TCA), for the treatment of depression and anxiety. In addition to single drug preparations, it is also available as Deanxit, marketed by Lundbeck, a combination product containing both melitracen and flupentixol.
Research
128 papers- Melitracen and flupentixol (deanxit) use disorder in Lebanon.Heliyon · 2023
- Flupentixol/melitracen for chronic refractory cough after treatment failure with other neuromodulators.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2021
- Efficacy and safety of flupentixol-melitracen in patients with refractory chronic cough: a randomised, double-blinded, placebo-controlled clinical trial.EClinicalMedicine · 2025
- The Efficacy of Flupentixol-Melitracen in the Adjuvant Therapy of Ulcerative Colitis in the Chinese Population: A Meta-Analysis.Gastroenterology research and practice · 2019
- Case report: Extrapontine myelinolysis combined with flupentixol- and melitracen-induced dysphagia.Frontiers in pharmacology · 2023
via PubMed
~1 min read
Encyclopedic overview
2 sectionsContents
- See also
- References
Melitracen (brand names Melixeran, Trausabun) is a tricyclic antidepressant (TCA), for the treatment of depression and anxiety. In addition to single drug preparations, it is also available as Deanxit, marketed by Lundbeck, a combination product containing both melitracen and flupentixol.
The pharmacology of melitracen has not been properly investigated and is largely unknown, but it is likely to act in a similar manner to other TCAs. Indeed, melitracen is reported to have imipramine and amitriptyline-like effects and efficacy against depression and anxiety, though with improved tolerability and a somewhat faster onset of action.
Excerpted from Wikipedia’s “melitracen” article, available under the CC BY-SA 4.0 licence.
Available in 10 languages
via Wikidata sitelinks · CC0